The relation of the frequency and functional molecules expression on plasmacytoid dendritic cells to postpartum hepatitis in women with HBeAg-positive chronic hepatitis B virus infection

被引:2
作者
Wang, Fuchuan [1 ]
Song, Meiying [2 ]
Hu, Yuhong [1 ]
Yang, Liu [3 ]
Bi, Xiaoyue [3 ]
Lin, Yanjie [4 ]
Jiang, Tingting [3 ]
Deng, Wen [3 ]
Wang, Shiyu [3 ]
Sun, Fangfang [3 ]
Zeng, Zhan [4 ]
Lu, Yao [3 ]
Shen, Ge [3 ]
Liu, Ruyu [3 ]
Chang, Min [3 ]
Wu, Shuling [3 ]
Gao, Yuanjiao [3 ]
Hao, Hongxiao [3 ]
Xu, Mengjiao [3 ]
Chen, Xiaoxue [3 ]
Hu, Leiping [3 ]
Wan, Gang [5 ]
Zhang, Lu [3 ]
Li, Minghui [3 ,4 ]
Xie, Yao [3 ,4 ]
机构
[1] Capital Med Univ, Beijing Ditan Hosp, Dept Gynecol & Obstet, Beijing, Peoples R China
[2] Capital Med Univ, Fu Xing Hosp, Dept Gynecol & Obstet, Beijing, Peoples R China
[3] Capital Med Univ, Beijing Ditan Hosp, Dept Hepatol, Div 2, Beijing, Peoples R China
[4] Peking Univ, Dept Hepatol, Ditan Teaching Hosp, Div 2, Beijing, Peoples R China
[5] Capital Med Univ, Beijing Ditan Hosp, Dept Med Records, Beijing, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
plasmacytoid dendritic cells; chronic hepatitis B; antiviral treatment; postpartum; immunity; PREDICTORS; IMMATURE; FLARES; IFN;
D O I
10.3389/fimmu.2022.1062123
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
ObjectiveTo explore the correlation between postpartum hepatitis and changes of plasmacytoid dendritic cells' (pDC) function and frequency in hepatitis B e antigen (HBeAg)-positive pregnant women with chronic hepatitis B virus (HBV) infection. MethodsPregnant women with chronic HBV infection receiving antiviral treatment (treated group) or not receiving antiviral treatment (untreated group) were enrolled and demographic information was collected before delivery. Clinical biochemical, virological serology, pDC frequency and functional molecular expression were tested before delivery and at 6, 12, 24 weeks after delivery. Results90 eligible pregnant women were enrolled, 36 in the untreated group and 54 in the treated group. 36 patients developed postpartum hepatitis, including 17 (17/36, 47.2%) in the untreated group and 19 (19/54, 35.2%) in the treated group (chi 2 = 1.304 p=0.253), and 22 cases of hepatitis occurred at 6 weeks postpartum, 12 at 12 weeks postpartum, and 2 at 24 weeks postpartum. The alanine transaminase (ALT) levels at any time postpartum were significantly higher than that of the antepartum, especially at 6 weeks and 12 weeks postpartum. However, the frequencies of pDCs, CD83(+) pDCs and CD86(+) pDCs antepartum had no significant difference from any time postpartum. The frequencies of CD83(+) pDCs, CD86(+) pDCs in the treated group antepartum were significantly higher than those in the untreated group [12.70 (9.46, 15.08) vs. 10.20 (7.96, 11.85), p=0.007; 22.05 (19.28, 33.03) vs. 18.05 (14.33, 22.95), p=0.011], and the same at 12 weeks postpartum [12.80 (10.50, 15.50) vs. 9.38 (7.73, 12.60), p=0.017; 22.50 (16.80, 31.20) vs. 16.50 (12.65, 20.80), p=0.001]. The frequency of CD86(+) pDCs in the treated group was significantly higher than that in the untreated group at 24 weeks postpartum [22.10 (16.70, 30.00) vs. 17.10 (13.70, 20.05), p=0.006]. ConclusionsPostpartum hepatitis in HBV infected women mainly occurs at 6-12 weeks postpartum. Antiviral treatment during pregnancy can significantly increase the frequencies of CD83(+) pDCs and CD86(+) pDCs in pregnant women with chronic HBV infection.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate
    Marcellin, Patrick
    Buti, Maria
    Krastev, Zahari
    de Man, Robert A.
    Zeuzem, Stefan
    Lou, Lillian
    Gaggar, Anuj
    Flaherty, John F.
    Massetto, Benedetta
    Lin, Lanjia
    Dinh, Phillip
    Subramanian, G. Mani
    McHutchison, John G.
    Flisiak, Robert
    Gurel, Selim
    Dusheiko, Geoffrey M.
    Heathcote, E. Jenny
    [J]. JOURNAL OF HEPATOLOGY, 2014, 61 (06) : 1228 - 1237
  • [22] Prediction of Spontaneous HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients During the Immune Clearance Phase
    Song, Guangjun
    Rao, Huiying
    Feng, Bo
    Wei, Lai
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2014, 86 (11) : 1838 - 1844
  • [23] Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysis
    Banerjee, S.
    Gunda, P.
    Drake, R. F.
    Hamed, K.
    [J]. SPRINGERPLUS, 2016, 5
  • [24] Why do I treat HBeAg-positive chronic hepatitis B patients with a Nucleoside analogue
    Ma, Hong
    Jia, Jidong
    [J]. LIVER INTERNATIONAL, 2013, 33 : 133 - 136
  • [25] Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels
    Lv, Guo-Cai
    Ma, Wen-Jiang
    Ying, Lin-Jung
    Jin, Xi
    Zheng, Lin
    Yang, Yi-Da
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (32) : 4095 - 4099
  • [26] Abnormal IL-10 levels were related to alanine aminotransferase abnormalities during postpartum in HBeAg positive women with chronic hepatitis B
    Wang, Ming
    Hou, Ying
    Meng, Shi-Hui
    Yang, Bo
    Yang, Ping
    Zhang, Hua
    Zhu, Yunxia
    [J]. MEDICINE, 2019, 98 (46) : e17969
  • [28] Cost-Effectiveness Analysis of Antiviral Treatments for HBeAg-Positive Chronic Hepatitis B in Canada
    He, Jing
    Bowen, James M.
    Xie, Feng
    Goeree, Ron
    [J]. VALUE IN HEALTH, 2012, 15 (06) : 894 - 906
  • [29] Tailored regimen of interferon alpha for HBeAg-positive chronic hepatitis B: a prospective controlled study
    Luo, K.
    Mao, Q.
    Karayiannis, P.
    Liu, D.
    Liu, Z.
    Zhou, Y.
    Feng, X.
    Zhu, Y.
    Guo, Y.
    Jiang, R.
    Zhou, F.
    Peng, J.
    Hou, J.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2008, 15 (09) : 684 - 689
  • [30] Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT
    Duan, Menghui
    Xiao, Huanming
    Shi, Meijie
    Xie, Yubao
    Zhao, Pengtao
    Li, Sheng
    Chi, Xiaoling
    Liu, Xueen
    Zhuang, Hui
    [J]. BMC INFECTIOUS DISEASES, 2024, 24 (01)